Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,334 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

NCT01188564
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
rhC1INH, Placebo (Saline)
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

NCT01191398
View directory record Official record
Conditions
Sialorrhea
Interventions
Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%
Drug
Lead sponsor
Craig J. Huang
Other
Eligibility
6 Months to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Recruiting Phase 4 Interventional

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

NCT07131592
View directory record Official record
Conditions
Drain Output After Breast Reduction Surgery, Breast Reductions
Interventions
IV TXA, Topical TXA, Topical saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

NCT01970345
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
IGF-1, Placebo/saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Inflammatory Challenge in Human Aggression.

NCT06665074
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Endotoxin (E. coli O:113, Reference Endotoxin), Saline (Placebo)
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

NCT06691217
View directory record Official record
Conditions
Vascular Inflammation, ASCVD, ASCVD Management
Interventions
CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

NCT03838133
View directory record Official record
Conditions
Hallux Valgus
Interventions
TLC590, Naropin®, Normal Saline, Bupivacaine
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversal of General Anesthesia With Methylphenidate

NCT02051452
View directory record Official record
Conditions
Post Operative Cognitive Dysfunction, Emergence From Anesthesia
Interventions
Methylphenidate, Saline
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 3 Interventional

Hymovis™ Versus Placebo in Knee Osteoarthritis

NCT01372475
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection
Device · Procedure
Lead sponsor
Fidia Farmaceutici s.p.a.
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Ideal Time of Oxytocin Infusion During Cesarean Section

NCT03246919
View directory record Official record
Conditions
Blood Loss, Surgical, Postpartum Hemorrhage, Bleed Pregnancy, Pregnancy Related, Cesarean Section Complications
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

NCT00123630
View directory record Official record
Conditions
Esophagitis
Interventions
omalizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

NCT02184156
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
4 mL injection of Ampion, 4 mL injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis

NCT03717896
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
200mg IV thiamine in 50mL 0.9% saline, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

NCT03453541
View directory record Official record
Conditions
Analgesic Adverse Reaction
Interventions
Ketorolac Tromethamine, 0.9% Normal Saline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Years to 18 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Memory & Conditioning Under Anesthesia

NCT04062123
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Dexmedetomidine, Propofol, Fentanyl, Peripheral Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 39 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 15, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional

CNP-201 in Subjects With Peanut Allergy

NCT05250856
View directory record Official record
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 15, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

NCT02651324
View directory record Official record
Conditions
Idiopathic Scoliosis, Post-operative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 15, 2026, 5:35 PM EDT